Mechanism of action
Nitrofurantoin is a prodrug that is reduced by bacterial flavoproteins (nitroreductases) to highly reactive intermediates. These metabolites cause multiple sites of damage:
- DNA strand breaks and cross-linking
- Disruption of ribosomal proteins
- Interference with bacterial enzyme systems involved in carbohydrate metabolism
The drug is bactericidal at therapeutic urine concentrations against most common urinary pathogens. Because mammalian cells lack the specific nitroreductases present in bacteria, selective toxicity is achieved.
Spectrum of activity
Nitrofurantoin is active against:
- Escherichia coli (most common uropathogen)
- Staphylococcus saprophyticus
- Enterococcus faecalis
- Some strains of Klebsiella and Enterobacter
Intrinsically resistant organisms include Pseudomonas aeruginosa, Proteus species, Serratia, and Acinetobacter. Resistance develops slowly because of the multiple intracellular targets.
- Nitrofurantoin causes chronic pulmonary fibrosis with long-term use, presenting as progressive dyspnea and interstitial infiltrates.
- Contraindicated in G6PD deficiency due to risk of severe hemolytic anemia.
- Only effective for lower UTI (cystitis); does NOT treat pyelonephritis or achieve tissue concentrations.
- Avoid in renal impairment (CrCl <30-60 mL/min): ineffective urine levels and increased systemic toxicity.
- Contraindicated at term pregnancy (38-42 weeks) and in neonates <1 month due to hemolysis risk.
- Acute pulmonary reaction presents with fever, dyspnea, eosinophilia within 1-2 weeks of starting therapy.
- Peripheral neuropathy risk increases with renal dysfunction, diabetes, or prolonged use.
- Bacterial nitroreductases convert nitrofurantoin to reactive intermediates that damage DNA and proteins.
Indications
Nitrofurantoin is FDA-approved for:
- Uncomplicated lower urinary tract infections (acute cystitis) caused by susceptible organisms
- Prophylaxis of recurrent UTIs in patients with frequent reinfections
Key limitations
Nitrofurantoin should not be used for:
- Pyelonephritis or upper UTI (inadequate tissue penetration)
- Complicated UTIs with systemic involvement
- Prostatitis (poor prostatic tissue concentration)
- Infections outside the urinary tract
It achieves therapeutic levels only in urine, not in blood or tissue, making it ineffective for systemic infections.
Pharmacokinetics
Absorption: Rapidly and completely absorbed from the GI tract. The macrocrystalline formulation causes less nausea than microcrystalline. Food increases absorption and bioavailability.
Distribution: Does not achieve therapeutic concentrations in blood or tissue. Concentrates in urine where bactericidal levels are reached. Crosses the placenta and enters breast milk.
Metabolism: Rapidly metabolized in tissues and the liver. Approximately 30-40% is excreted unchanged in urine.
Excretion: Renal elimination via glomerular filtration and tubular secretion. Requires adequate renal function (CrCl ≥30-60 mL/min depending on guidelines) to achieve effective urine concentrations. In renal impairment, the drug accumulates in serum (increasing toxicity risk) while urine levels fall below therapeutic thresholds.
Half-life: Approximately 20 minutes in patients with normal renal function.
The brown or dark yellow discoloration of urine is a harmless effect and should be explained to patients.
Adverse effects
Pulmonary toxicity (most high-yield)
Acute pulmonary reaction (1-2 weeks of therapy):
- Fever, dyspnea, cough, chest pain
- Eosinophilia and pulmonary infiltrates on imaging
- Resolves with discontinuation
Chronic pulmonary fibrosis (months to years of therapy):
- Insidious onset of dyspnea and cough
- Interstitial fibrosis on CT scan
- May be irreversible even after stopping the drug
- Classic USMLE association: elderly woman on long-term UTI prophylaxis presenting with progressive dyspnea
Gastrointestinal
- Nausea, vomiting, anorexia (common, dose-related)
- Taking with food or using macrocrystalline formulation reduces GI upset
Neurologic
- Peripheral neuropathy (especially with renal impairment or prolonged use)
- Headache, dizziness
Hematologic
- Hemolytic anemia in G6PD deficiency (absolute contraindication)
- Megaloblastic anemia (rare, with long-term use)
Hepatotoxicity
- Acute or chronic hepatitis (rare)
- Cholestatic jaundice
- Monitor liver enzymes if symptoms develop
Hypersensitivity
- Rash, urticaria, angioedema
- Drug-induced lupus (rare)
Other
- Brown discoloration of urine (harmless)
- Superinfection with resistant organisms or fungi
Contraindications and warnings
Absolute contraindications
- G6PD deficiency (risk of severe hemolytic anemia)
- Significant renal impairment (CrCl <30-60 mL/min; ineffective and increased toxicity)
- Pregnancy at term (38-42 weeks), labor and delivery, or neonates <1 month (risk of hemolytic anemia in newborn)
- Anuria or oliguria
- Known hypersensitivity to nitrofurantoin
Warnings and precautions
Pulmonary toxicity: Monitor for respiratory symptoms, especially in elderly patients or those on long-term therapy. Baseline and periodic pulmonary function tests may be considered for chronic use.
Hepatotoxicity: Discontinue if signs of hepatic injury develop. Rare cases of fatal hepatic necrosis have been reported.
Peripheral neuropathy: Risk increases with renal dysfunction, anemia, diabetes, electrolyte imbalance, and vitamin B deficiency. May be irreversible.
Pregnancy: Category B. Generally avoided in first trimester due to limited data. Contraindicated at term.
Lactation: Excreted in breast milk. Contraindicated if infant has G6PD deficiency or is <1 month old.
Elderly: Increased risk of pulmonary and hepatic toxicity. Use with caution, especially for long-term prophylaxis.
Drug interactions
Magnesium trisilicate antacids: Decrease nitrofurantoin absorption. Space administration.
Probenecid and sulfinpyrazone: Inhibit renal tubular secretion of nitrofurantoin, decreasing urinary concentrations and increasing serum levels (increased toxicity, decreased efficacy).
Quinolone antibiotics: Nitrofurantoin may antagonize the antibacterial effect of quinolones in the urinary tract. Avoid concurrent use.
Hepatotoxic drugs: Use caution when combining with other hepatotoxic agents.
Anticholinergic drugs: May delay gastric emptying and increase nitrofurantoin absorption, potentially increasing adverse effects.
Fluoroquinolones (norfloxacin): In vitro antagonism reported; clinical significance uncertain but concurrent use generally avoided.
No significant interactions with warfarin or oral contraceptives.
Clinical pearls
- Only for lower UTI: Nitrofurantoin is ineffective for pyelonephritis, prostatitis, or any systemic infection because it does not reach therapeutic tissue concentrations.
- Avoid in renal impairment: Below CrCl 30-60 mL/min, the drug is both ineffective (inadequate urine levels) and toxic (serum accumulation). The Beers Criteria list nitrofurantoin as potentially inappropriate in elderly patients with CrCl <30 mL/min.
- G6PD screening: Always screen or ask about G6PD deficiency, especially in high-risk populations (Mediterranean, African, Middle Eastern, Southeast Asian ancestry).
- Duration matters: Acute cystitis typically requires 5-7 days of therapy. For prophylaxis, use the lowest effective dose, but monitor for pulmonary and hepatic toxicity.
- Urine color: Warn patients about harmless brown or yellow discoloration of urine to improve adherence.
- Macrocrystalline formulation: Better tolerated than microcrystalline with less GI upset. Always administer with food.
- Resistance patterns: Nitrofurantoin retains excellent activity against E. coli despite widespread fluoroquinolone and TMP-SMX resistance, making it a valuable option for uncomplicated cystitis.
- Pregnancy considerations: While category B, many guidelines recommend avoiding in first trimester and absolutely contraindicated at term due to neonatal hemolysis risk.
- Long-term prophylaxis risks: Weigh benefits against risks of chronic pulmonary fibrosis, peripheral neuropathy, and hepatotoxicity. Consider alternative strategies (e.g., post-coital prophylaxis, behavioral modification).
- Not for empiric pyelonephritis: A classic exam error is using nitrofurantoin for febrile UTI or flank pain—always choose a drug with good tissue penetration (fluoroquinolone, ceftriaxone, or TMP-SMX if susceptible).
NITRO-Furan pulmonary and renal concerns: No G6PD deficiency, Ineffective in renal failure, Term pregnancy contraindicated, Respiratory fibrosis (chronic), Only for lower UTI (not pyelonephritis).
Practice questions
1. A 72-year-old woman with recurrent urinary tract infections has been taking nitrofurantoin prophylaxis for 18 months. She presents with a 3-month history of progressive dyspnea on exertion and dry cough. She denies fever or chest pain. Vital signs are normal except for oxygen saturation of 92% on room air. Chest X-ray shows bilateral interstitial infiltrates. Pulmonary function tests reveal a restrictive pattern. Which of the following is the most likely diagnosis?
2. A 28-year-old woman at 39 weeks gestation presents to the emergency department with fever, dysuria, and urinary frequency for 2 days. Urinalysis shows pyuria and bacteriuria. Which of the following antibiotics is contraindicated at this stage of pregnancy?
3. A 45-year-old man of Mediterranean descent develops dark urine and jaundice 3 days after starting nitrofurantoin for a urinary tract infection. Laboratory studies show hemoglobin 8.5 g/dL (baseline 14 g/dL), elevated indirect bilirubin, elevated LDH, low haptoglobin, and a peripheral smear with bite cells and Heinz bodies. Which of the following is the most likely underlying condition?
Frequently asked questions
How does nitrofurantoin work?
Nitrofurantoin is reduced by bacterial nitroreductase enzymes to reactive intermediates that damage bacterial DNA, proteins, and cell membranes. This multi-target mechanism provides bactericidal activity against common uropathogens like E. coli. Because mammalian cells lack these specific bacterial enzymes, selective toxicity is achieved. The drug concentrates in urine but does not reach therapeutic levels in blood or tissue.
What are the side effects of nitrofurantoin?
The most serious side effects are pulmonary toxicity (acute pneumonitis or chronic interstitial fibrosis), especially with long-term use. Nitrofurantoin also causes hemolytic anemia in patients with G6PD deficiency, peripheral neuropathy (especially with renal impairment), hepatotoxicity, and GI upset (nausea, vomiting). Common but harmless effects include brown or yellow urine discoloration. Long-term use requires monitoring for lung and liver complications.
Can nitrofurantoin treat kidney infections?
No, nitrofurantoin should not be used for kidney infections (pyelonephritis). It only achieves bactericidal concentrations in urine, not in kidney tissue or blood. Upper urinary tract infections require antibiotics with good tissue penetration such as fluoroquinolones, third-generation cephalosporins, or trimethoprim-sulfamethoxazole. Using nitrofurantoin for pyelonephritis is ineffective and delays appropriate treatment.
Is nitrofurantoin safe during pregnancy?
Nitrofurantoin is FDA pregnancy category B and is generally considered safe during the second and early third trimester for treating UTIs. However, it should be avoided in the first trimester when possible due to limited safety data. It is absolutely contraindicated at term (38-42 weeks gestation), during labor and delivery, and in neonates under 1 month due to the risk of hemolytic anemia in the newborn.
Nitrofurantoin vs trimethoprim-sulfamethoxazole — what is the difference?
Both treat uncomplicated UTIs, but nitrofurantoin only works in the bladder (lower UTI) while TMP-SMX achieves tissue levels and can treat pyelonephritis and other systemic infections. Nitrofurantoin is often preferred when local E. coli resistance to TMP-SMX exceeds 20%. TMP-SMX has more drug interactions and higher rates of resistance in many areas. Nitrofurantoin is contraindicated in renal impairment and G6PD deficiency, while TMP-SMX requires dose adjustment in renal disease and causes folate-related side effects.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J01XE01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.